Table 2.

Results of one-way sensitivity analyses: variation in annual cost of single-tablet regimen and incremental cost-effectiveness ratio (ICER)

STR cost per year	% increase	ICER	% increase	TDF-FTC + EFV (MPR) cost per year	% decrease	ICER	% decrease
€7,226	0%	22,017	0%	7,226	0%	26,558	0%
€7,298	1%	22,173	1%	7,154	−1%	26,366	−1%
€7,371	2%	22,330	1%	7,081	−2%	26,178	−1%
€7,443	3%	22,486	2%	7,009	−3%	25,990	−2%
€7,515	4%	22,642	3%	6,937	−4%	25,801	−3%
€7,587	5%	22,799	4%	6,865	−5%	25,612	−4%
€7,660	6%	22,955	4%	6,792	−6%	25,423	−4%
€7,732	7%	23,111	5%	6,720	−7%	25,234	−5%
€7,804	8%	23,267	6%	6,648	−8%	25,045	−6%
€7,876	9%	23,424	6%	6,576	−9%	24,856	−6%
€7,949	10%	23,580	7%	6,503	−10%	24,667	−7%
€8,021	11%	23,736	8%	6,431	−11%	24,478	−8%
€8,093	12%	23,893	9%	6,359	−12%	24,289	−9%
€8,165	13%	24,049	9%	6,287	−13%	24,100	−9%
€8,238	14%	24,205	10%	6,214	−14%	23,912	−10%
€8,310	15%	24,362	11%	6,142	−15%	23,723	−11%
€8,382	16%	24,518	11%	6,070	−16%	23,534	−11%
€8,454	17%	24,674	12%	5,998	−17%	23,345	−12%
€8,527	18%	24,830	13%	5,925	−18%	23,156	−13%
€8,599	19%	24,987	13%	5,853	−19%	22,967	−14%
€8,671	20%	25,143	14%	5,781	−20%	22,778	−14%
€8,743	21%	25,299	15%	5,709	−21%	22,589	−15%
€8,816	22%	25,456	16%	5,636	−22%	22,400	−16%
€8,888	23%	25,612	16%	5,564	−23%	22,211	−16%
€8,960	24%	25,768	17%	5,492	−24%	22,017	−17%
€9,033	25%	25,925	18%	5,420	−25%	21,834	−18%
€9,105	26%	26,081	18%	5,347	−26%	21,645	−19%
€9,177	27%	26,237	19%	5,275	−27%	21,456	−19%
€9,249	28%	26,393	20%	5,203	−28%	21,267	−20%
€9,322	29%	26,550	21%	5,130	−29%	21,078	−21%
€9,318	29%	26,558	21%	5,058	−30%	20,889	−21%
€9,394	30%	26,706	21%	4,986	−31%	20,700	−22%

Abbreviations: EFV, efavirenz; ICER, incremental cost-effectiveness ratio; MPR, multipill regimen; STR, single-tablet regimen; TDF, tenofovir; FTC, emtricitabine.